|BPC is not patentable, and thus not interesting for BigPharma.|
Studies as they were published by Brcic, et al. in the J Physiol Pharmacol in 2009. A study in cell cultures and living rodents whose crushed muscles and transected muscle and tendons didn't heal magically, but a comparison of the animals who received BPC 157 at a dosage of 10 µg (human equivalent 5.4 µg/kg) dissolved in saline to those who were treated with an equivalent volume of saline alone (5 ml/kg) showed a sign. accelerated response of the measured cell antigens, FVIII (involved in platelet adhesion and aggregation, present on endothelial cells of mature blood vessels) and CD34 (involved in leukocyte adhesion and endothelial cell migration during angiogenesis, present on capillary endothelial cells), as well as VEGF (Figure 1):
|Figure 1: All markers of inflammation and muscle repair were sign. elevated with oral BPC-157(solid live) vs. control treatment with saline (dashed line) treatment in a model of muscle injury (Brcic. 2009).|
- promote tendon & ligament healing by tendon outgrowth, cell survival, and cell migration as it was observed in a rodent model of Achilles tendon rupture (Chang. 2011), and when administered in the drinking water to rats with experimentally damaged medial collateral ligaments (Cerovecki. 2010)
- direct tendon-to-bone healing so effectivel that they may actually "successfully exchange the present reconstructive surgical methods" (Krivic. 2006),
- counter the damaging effects of NSAIDs on the gut lining so effectively that scientists call BPC 157 "a NSAIDs antidote" one of which they say that "no other single agent has portrayed a similar array of effects" (Sikiric. 2013),
- repair the damage that's done by inflammatory bowel disease within days of oral administration in µg or ng doses in a rodent model of IBS (Vuksic. 2007),
- help cure perdidontitis when it is chronically administered in a rodent model of periodontitis potently enough to have scientists conclude that "BPC 157 may represent a new peptide candidate in the treatment of periodontal disease" (Keremi. 2009),
- reverse systemic corticosteroid-impaired muscle healing, in a rodent model where it was administered with a front-load of 10µg orally once daily for 14 days to rats w/ crushed gastrocnemius muscle (Pevec. 2010 | similar benefits in a rodent study by Novinscak et al. that was published in Surgery Today in 2008), and
- bone healing in rabbits who suffered an experimental segmental bone defect before being treated with BPC-157 (Šebečić. 1999).
Cool? Well, I guess your next question is: "What's the necessary dosage?" If we use the existing rodent data as a yardstick, the answer to this question is ca. 5µg/kg body weight (Novinscak. 2008; Cerovecki. 2010). That's ~400µg per day for an 80kg man and thus roughly what you will see people on the Internet say they use.
Want to listen to me explain the study? Plus: Update! Download yesterday's installment of the SuppVersity Science-Round-Up at SuperHumanRadio.com | click here to download! On another note, after this article was originally published I received word from someone who claims to know the researchers who did the original studies and cautions against putting to much faith into their results... that is yet not the main argument for me; rather than that I am only skeptically optimistic, because no human studies have confirmed the efficacy of the compound.Without a human study that would conform that you need that much / that much little is sufficient, it is yet impossible to provide a science-backed recommended dosage for optimal effects at minimal side effects (chronic consumption not suggested, yet | learn why).
|Figure 2: Pevec et al. didn't just observe that BPC-157 blocked the ill effects of corticosteroids on muscle healing, they also found that BPC-157 alone super-charged the healing process (Pevec. 2010).|
- Brcic, L., et al. "Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing." J Physiol Pharmacol 60.Suppl 7 (2009): 191-196.
- Cerovecki, Tomislav, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." Journal of orthopaedic research 28.9 (2010): 1155-1161.
- Chang, Chung-Hsun, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology 110.3 (2011): 774-780.
- Chang, Chung-Hsun, et al. "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules 19.11 (2014): 19066-19077.
- Keremi, B., et al. "Antiinflammatory effect of BPC 157 on experimental periodontitis in rats." Journal of physiology and pharmacology 60.7 (2009): 115-122.
- Krivic, Andrija, et al. "Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon‐to‐Bone Healing and Opposed Corticosteroid Aggravation." Journal of orthopaedic research 24.5 (2006): 982-989.
- Novinscak, Tomislav, et al. "Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat." Surgery today 38.8 (2008): 716-725.
- Pevec, Danira, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor 16.3 (2010): BR81-BR88.
- Šebečić, Božidar, et al. "Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation." Bone 24.3 (1999): 195-202.
- Sikirić, Predrag, et al. "A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC." Journal of Physiology-Paris 87.5 (1993): 313-327.
- Sikiric, Predrag, et al. "The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H 2 receptor antagonists, dopamine promotors and gut peptides." Life sciences 54.5 (1994): PL63-PL68.
- Sikiric, Predrag, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current pharmaceutical design 19.1 (2013): 76-83.
- Vuksic, Tihomir, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat." Surgery today 37.9 (2007): 768-777.